These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Arnaud L; Mathian A; Devilliers H; Ruffatti A; Tektonidou M; Forastiero R; Pengo V; Lambert M; Lefevre G; Martinez-Zamora MA; Balasch J; Wahl D; Amoura Z Autoimmun Rev; 2015 Mar; 14(3):192-200. PubMed ID: 25461472 [TBL] [Abstract][Full Text] [Related]
12. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Erkan D; Harrison MJ; Levy R; Peterson M; Petri M; Sammaritano L; Unalp-Arida A; Vilela V; Yazici Y; Lockshin MD Arthritis Rheum; 2007 Jul; 56(7):2382-91. PubMed ID: 17599766 [TBL] [Abstract][Full Text] [Related]
13. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963 [TBL] [Abstract][Full Text] [Related]
14. Antiphospholipid antibodies in critical illness. Dentali F; Crowther M Crit Care Med; 2010 Feb; 38(2 Suppl):S51-6. PubMed ID: 20083914 [TBL] [Abstract][Full Text] [Related]
15. [Management of antiphospholipid syndrome]. Saadoun D; Piette JC; Wahl D; Costedoat-Chalumeau N Rev Med Interne; 2012 Apr; 33(4):217-22. PubMed ID: 22360832 [TBL] [Abstract][Full Text] [Related]
16. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Wahl DG; Bounameaux H; de Moerloose P; Sarasin FP Arch Intern Med; 2000 Jul; 160(13):2042-8. PubMed ID: 10888978 [TBL] [Abstract][Full Text] [Related]
17. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Yelnik CM; Urbanski G; Drumez E; Sobanski V; Maillard H; Lanteri A; Morell-Dubois S; Caron C; Dubucquoi S; Launay D; Duhamel A; Hachulla E; Hatron PY; Lambert M Lupus; 2017 Feb; 26(2):163-169. PubMed ID: 27432808 [TBL] [Abstract][Full Text] [Related]
18. Clinical profiles and risk assessment in patients with antiphospholipid antibodies. Kato M; Hisada R; Atsumi T Expert Rev Clin Immunol; 2019 Jan; 15(1):73-81. PubMed ID: 30381978 [TBL] [Abstract][Full Text] [Related]
19. Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018? Zuo Y; Barbhaiya M; Erkan D Curr Rheumatol Rep; 2018 Sep; 20(11):66. PubMed ID: 30203272 [TBL] [Abstract][Full Text] [Related]
20. [The management of thrombosis in the antiphospholipid antibody syndrome: insights from recent clinical trials and remaining unsolved issues]. Wahl D; Perret-Guillaume C; Piette JC Rev Med Interne; 2008 Sep; 29(9):731-4. PubMed ID: 18584919 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]